Stock AnalizIonis Pharmaceuticals Inc. IONS
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Ionis Pharmaceuticals Inc. (IONS) is a healthcare company listed in the US with a market value of about $4.8B. In the twelve months to September 30, 2026 it had revenue of $960M and net income of -$547M, a net margin of -56.9%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 5% a year, a 5-year average ROIC of -14%.
Score: 0.8 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $960M | $944M | $705M | $788M | $587M | $810M | $729M | $1.1B | $600M | $508M | $373M |
| Net income | -$547M | -$381M | -$454M | -$366M | -$270M | -$29M | -$444M | $278M | $274M | $346000 | -$60M |
| Free cash flow | -$616M | -$320M | -$546M | -$331M | -$290M | $19M | $772000 | $315M | $589M | $139M | -$119M |
| EPS (diluted) | $-3.32 | $-2.38 | $-3.04 | $-2.56 | $-1.90 | $-0.20 | $-3.18 | $1.90 | $2.07 | $0.15 | $-0.50 |
| Net margin | -56.9% | -40.4% | -64.4% | -46.5% | -45.9% | -3.5% | -60.9% | 24.8% | 45.6% | 0.1% | -16.2% |
| ROIC | — | -11.7% | -23.3% | -14.9% | -16.6% | -3.7% | -8.5% | 13.6% | -3.0% | 2.5% | -2.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 23 analysts is $68.48, 136% above the current price; targets range from $41.00 to $105.00; the consensus rating is “Buy”; expected EPS is $-2.44 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Ionis Pharmaceuticals pay a dividend?
Not currently.
Is Ionis Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Ionis Pharmaceuticals scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.